Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Neurofibroma, Plexiform × cabozantinib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 14 Neoplasms 6 Neoplasm Metastasis 5 Carcinoma, Non-Small-Cell Lung 5 Prostatic Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Hepatocellular 4 Triple Negative Breast Neoplasms 3 Sarcoma, Ewing 3 Ovarian Neoplasms 3 Melanoma 3 Kidney Neoplasms 3 Carcinoma, Transitional Cell 3 Pancreatic Neoplasms 2 Osteosarcoma 2 Multiple Myeloma 2 Leukemia, Myeloid, Acute 2 HIV Infections 2 Endometrial Neoplasms 2 Carcinoma, Medullary 2 Breast Neoplasms 2 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Thyroid Neoplasms 1 Thrombocytosis 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Kaposi 1

Interventions

AZD 6244 2 pirfenidone 1 cabozantinib 1 Sorafenib 1 Pharmacokinetics 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06502171 2026-03-12

NF113

University of Alabama at Birmingham

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡